David Hutton

Previous research conducted primarily by scientists at the University of São Paulo, Brazil, showed brilacidin can potentiate several marketed antifungals, including caspofungin, voriconazole and posaconazole.

The company confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024. The data will also play an important supporting role in U.S. regulatory submission.

STAAR Surgical President and CEO Caren Mason will be retiring December 31, and ophthalmic industry executive Thomas “Tom” G. Frinzi has been tapped as her replacement.

Company officials point out that RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye.

Runa Capital-led funding will help scale the AI-powered eye pathology detection solution.

Ophthalmology Times®' EyeCon co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute, and glaucoma specialist Oluwatosin U. Smith MD, from Glaucoma Associates of Texas, discuss some of the highlights of EyeCon 2022.

The test is slated for further clinical development in the first quarter of 2023 and, once FDA approved, will be added to the company's catalog of ophthalmological diagnostic tools available to clinicians throughout North America.

The company is poised to roll out its eye-tracking amblyopia treatment to the U.S. market.

According to the study, attendance improved by 9% and the return on investment totaled $11,387 over a 12-week period.

The IDMC recommended continuation of the study based upon the outcome of the futility analysis.

Harrow Health Inc. announced it has agreed to purchase the exclusive U.S. commercial rights to 5 ophthalmic drugs from Novartis AG for up to $175 million, the company announced today.

The partnership was formalized at the recent International Conference for Initiatives on Organ and Tissue Donation and Transplantation in Abu Dhabi.

Under the terms of the agreement, Ocular will pay Titan an upfront licensing fee with the potential for additional payments upon reaching certain milestones.

AZR-MD-001 is currently being studied to evaluate the safety, efficacy, and tolerability of the study drug in patients with MGD.

The results represent a major step towards first in-human clinical studies for this program - the first potential therapy for patients with geographic atrophy secondary to AMD that addresses the underlying causes of the disease.

The Ernest E. Tschannen Eye Institute is dedicated to eye care and sight restoration through technology, pioneering research and eye care clinicians.

According to the company, the NDA is supported by positive phase data demonstrating the rapid reversal of dilated eyes and favorable safety profile in pediatric and adult subjects.

Researchers from the Deutsches Zentrum für Neurodegenerative Erkrankungen and the Center for Regenerative Therapies Dresden at TU Dresden have found that visual cells in the human retina may not simply die in some diseases, but are mechanically transported out of the retina beforehand.

According to researchers, cells within retinal blood vessels are endowed with a previously unappreciated ability to acquire resistance against the damaging effects of hyperglycemia in patients with diabetes mellitus.

Researchers found through DNA sequencing and confirmed in further testing that a genetic mutation in the THBS1 gene led to the development of severe childhood glaucoma. The discovery may improve disease screening and personalize treatments.

SPVN06 is a breakthrough gene therapy approach aimed at stopping or slowing disease progression in patients affected by IRDs and dry age-related macular degeneration (AMD), regardless of their genetic background.

OPGx-001 is Opus’ first program to enter clinical evaluation and is designed to address vision loss due to mutations in the LCA5 gene, which causes one of the most severe forms of early-onset blinding disease Leber congenital amaurosis.

Aflibercept and bevacizumab are the two most frequently used therapies for the treatment of wet AMD.

According to the company, the facility will serve as a hub of the EVO Lens-Based Experience for ophthalmic surgeons, staff and healthcare practitioners.

In a two-decade career as a researcher at Johnson & Johnson Surgical Vision, Piers has been a part of teams at the forefront of a number of innovations in IOLs. She discusses her career and the outlook for research and development in ophthalmology.

Re-Vana has demonstrated that its platform can achieve 6 months or greater sustained delivery of an anti-VEGF biologic at therapeutically-relevant levels with high drug loading, controlled burst release, and a favorable degradation profile.

The deal will provide Harrow’s entire formulary compounded ophthalmic products to iOR Partners’ expanding office-based surgery locations across the United States.

According to investigators, retinal aging caused by stress produces symptoms similar to those resulting from natural aging.

The deal adds pharmaceutical research and development capabilities and further expertise for future product pipeline. It also expands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category.